# Junta clínica — PT-pseudo_fdd4ff09679e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_fdd4ff09679e",
  "pid": "PT-pseudo_fdd4ff09679e",
  "task": 1,
  "psa": 4.4,
  "age": 62,
  "months": 1,
  "pirads": "5",
  "psad": 0.048,
  "psav": 0.75,
  "psap": 4.0,
  "vol": 91.11,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.78277797,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.05. Prostate volume 91 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "97 kg",
    "height": "180 cm",
    "bmi": "29.9",
    "bp": "133/72 mmHg",
    "hr": "70 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. H. Martens (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested after previous prostate sampling and subsequent PSA elevation."
    },
    {
      "s": "History",
      "t": "At 62 years of age, this widowed gentleman entered evaluation in early 2023 due to an elevated PSA reading. Two subsequent biopsy procedures confirmed the prostate cancer diagnosis. He abstains from tobacco, consumes no alcohol, and manages moderate lower urinary tract symptoms, registering 13 points on the IPSS scale. Nocturia and acute urinary retention remain absent. A retired carpenter, he resides with his partner and dedicates weekends to hiking across nearby countryside. Cardiology evaluation in autumn 2024 indicated stable physiological parameters, while orthopaedic knee assessments reveal no functional restrictions. The patient historically favored adaptable clinic hours, though retirement has shifted that preference."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth; mobility: unremarkable; asymmetry: none. The examination confirms a normal DRE with a symmetrically enlarged prostate and firm capsule, lacking palpable nodules. Systemic assessment shows stable vital parameters. No lymphadenopathy or bone tenderness is evident."
    }
  ],
  "occupation": "retired carpenter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_fdd4ff09679e
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. H. Martens (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 62-year-old male
  - PSA: 4.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.048 ng/mL²
  - PSA velocity: 0.75 ng/mL/yr
  - Prior PSA: 4.0 ng/mL
  - Prostate volume: 91.11 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78277797 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.4 ng/mL. PI-RADS 5. PSAD 0.05. Prostate volume 91 mL. csPCa 0.78.

Vitals: weight 97 kg, height 180 cm, BMI 29.9, BP 133/72 mmHg, HR 70 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested after previous prostate sampling and subsequent PSA elevation.

History: At 62 years of age, this widowed gentleman entered evaluation in early 2023 due to an elevated PSA reading. Two subsequent biopsy procedures confirmed the prostate cancer diagnosis. He abstains from tobacco, consumes no alcohol, and manages moderate lower urinary tract symptoms, registering 13 points on the IPSS scale. Nocturia and acute urinary retention remain absent. A retired carpenter, he resides with his partner and dedicates weekends to hiking across nearby countryside. Cardiology evaluation in autumn 2024 indicated stable physiological parameters, while orthopaedic knee assessments reveal no functional restrictions. The patient historically favored adaptable clinic hours, though retirement has shifted that preference.

Physical examination: DRE — texture: smooth; mobility: unremarkable; asymmetry: none. The examination confirms a normal DRE with a symmetrically enlarged prostate and firm capsule, lacking palpable nodules. Systemic assessment shows stable vital parameters. No lymphadenopathy or bone tenderness is evident.

Patient info: retired carpenter; Widowed; Lives with partner.
Next of kin: Nephew.

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.11 epistemic (95% band 0.41-0.83); among patients I cannot tell apart the outcome was 0.96 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.75: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.76: PI-RADS 5, PSA 4.2, PSAD 0.06, age 67, DRE Nodus -> DEFER (uncertain). He wrote: "Need to know if the lesion has grown or if it is stabile."
  3. distance 1.78: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."

PRECEDENT: BIOPSY (weighted vote 0.67 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the decision to perform a biopsy based on the PI-RADS score and PSA density. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." For this patient, the PI-RADS score is 5 and the PSA density is 0.048 ng/mL², which falls into the lowest PSA-D category (< 0.10 ng/mL/cc).

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline suggests that for low-risk profiles, biopsy could have been avoided in 99 men while missing ISUP GG 2 cancers in only six men. EXPERT-COHORT, the finding that the panel does not determine the decision is correct, but the guideline suggests that variables like PSA density and prior biopsy status are significant predictors that should be weighed.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the trend of the PSA: a rising PSA is a factor that should be weighed in the decision
laboratory_results - the PSA density: the PSA density of 0.048 ng/mL² falls into the lowest risk category, which the guideline makes decisive

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI report indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the trend of the PSA?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is there a surveillance protocol in place?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI report indicates that the lesion is compared against an earlier study, as it is a re-evaluation after a prior diagnosis.
psa_trend
The trend of the PSA is a rising PSA, with values from "May 2023" at "1.5" to "Mar 2024" at "1.1" and "Jan 2025" at "4.4".
previous_notes
The documented grade of the prior biopsy is "ISUP GG 2", and there is no explicit mention of a surveillance protocol in place.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the key finding regarding PSA density was already addressed by the EXPERT-EAU in relation to the PI-RADS score.

WHAT THIS SUPPORTS
FOR sampling this patient now
The documented grade of the prior biopsy is "ISUP GG 2", which the EXPERT-EAU suggests sends him to treatment, not more tissue.
The rising PSA trend is a factor that should be weighed in the decision, as noted by EXPERT-EAU.
AGAINST sampling this patient now
The PSA density of 0.048 ng/mL² falls into the lowest risk category, which the EXPERT-EAU makes decisive.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.40 ng/mL over 3 points spanning 20 months; velocity +1.74 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 6.6 ng/mL, conformal 95% band 1.9-23.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.10 epistemic (95% band 0.40-0.80), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.62  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.60  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.67  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 2 ("ISUP GG 2")

RULE THAT FIRED: documented prior grade GG 2 (ISUP GG 2) — carried by documented grade.
PANEL ANSWER: NO BIOPSY. A documented grade group of 2 or more is a treatment problem, not a sampling problem: the reading urologist deferred re-biopsy in 7 of the 8 labelled men with a recorded GG >= 2.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-FUSION, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar—the radiology report, PSA trend, and previous notes—directly address the moderator's questions regarding the prior biopsy grade and surveillance status.

ALIGNMENT WITH THE PANEL
The retrieved finding, "ISUP GG 2" from the previous notes, aligns with the PANEL-PROTOCOL's decision of "NO BIOPSY," as the protocol states that a documented grade group of 2 or more is a treatment problem, not a sampling problem.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? Answered by the previous notes: "ISUP GG 2".
Q2. Is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the previous notes: "there is no explicit mention of a surveillance protocol in place."

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade ("ISUP GG 2") is the most critical variable because the PANEL-PROTOCOL explicitly states this finding dictates the decision, overriding other factors like the rising PSA trend or the low PSA density.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as "NO BIOPSY" based on the documented ISUP GG 2 grade, as this finding is explicitly weighted by the PANEL-PROTOCOL to indicate a treatment problem rather than a sampling problem.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

62y male, PSA 4.4, PSAD 0.048, PI-RADS 5, prior biopsy ISUP GG 2. Given documented prior diagnosis, repeat biopsy is not indicated as the lesion characterization is established. The PI-RADS 5 finding is consistent with known disease progression.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
